Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition (Tables)

v3.24.2.u1
Asset Acquisition (Tables)
6 Months Ended
Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Asset Acquisition
Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the Almata Transaction (in thousands):

Six Months Ended June 30, 2024
Stock consideration1
$ 12,272 
Milestone payment due upon close of private placement investment2
7,500 
Milestone payment due upon first patient dosed in a Phase 2 trial2
5,000 
Transaction costs 2,402 
Total GAAP Purchase Price at Close $ 27,174 
Acquired IPR&D $ 27,641 
Cash 356 
Accrued expenses and other current liabilities (823)
Total net assets acquired and liabilities assumed $ 27,174 

1 Equal to the aggregate common shares issued of 171,605 and the aggregate preferred shares issued of 2,412 (as-convertible to 2,412,000 shares of common stock), multiplied by the Company’s closing stock price of $4.75 on March 27, 2024.

2 Avalo deemed these milestones probable and estimable as of the transaction close date and therefore included them as part of the GAAP purchase price at close. The first milestone payment due upon the close of the private placement investment was met on March 28, 2024 and was paid on April 1, 2024.